DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Dopamine Hydrochloride In Dextrose 5% In Plastic Container, and when can generic versions of Dopamine Hydrochloride In Dextrose 5% In Plastic Container launch?

Dopamine Hydrochloride In Dextrose 5% In Plastic Container is a drug marketed by Baxter Hlthcare and Hospira and is included in two NDAs.

The generic ingredient in DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER is dopamine hydrochloride. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dopamine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dopamine Hydrochloride In Dextrose 5% In Plastic Container

A generic version of DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as dopamine hydrochloride by HOSPIRA on February 4^th, 1982.

Summary for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	1,103
DailyMed Link:	DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Krzysztof Bankiewicz	PHASE1
Cairo University	NA
Tanta University	NA

See all DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

Pharmacology for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Drug Class

Catecholamine

US Patents and Regulatory Information for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	019615-001	Mar 27, 1987	AP	RX	Yes	Yes
Hospira	DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	018826-003	Sep 30, 1983	AP	RX	Yes	Yes
Baxter Hlthcare	DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	dopamine hydrochloride	INJECTABLE;INJECTION	019615-004	Mar 27, 1987		RX	Yes	Yes

Market Analysis and Financial Outlook for Dopamine Hydrochloride in Dextrose 5% in Plastic Containers

Last updated: February 10, 2026

Market Size and Revenue Projection

The global market for dopamine hydrochloride in dextrose 5% solutions primarily serves critical care settings, including hospitals and infusion centers. The market was valued at approximately $250 million in 2022, driven by increasing cases of cardiovascular emergencies, sepsis, and critical illnesses. The compound’s therapeutic use in managing shock and heart failure sustains steady demand.

Forecasts project a compounded annual growth rate (CAGR) of 4.5% from 2023 to 2028, reaching approximately $320 million in revenue by 2028. The growth is driven by rising prevalence of cardiovascular conditions, aging populations, and expanding ICU capacities worldwide.

Competitive Landscape

Major manufacturers include:

• Pfizer
• Hospira (a Pfizer division)
• Baxter International
• Fresenius Kabi
• Sandoz

These companies control about 85% of the market share, with Pfizer and Hospira leading in supply volume and global distribution.

Market entry barriers include strict regulatory requirements, manufacturing standards (USP, EP), and the need for specialized sterile manufacturing facilities. The product’s stability in plastic containers influences packaging choices and supply chain logistics, affecting competitive positioning.

Pricing and Reimbursement Trends

Pricing varies regionally: in the US, per 100 mL dose averages $4 to $6; in Europe, roughly €3 to €5 per 100 mL. Reimbursement policies favor volume-based hospital procurement, with government and insurance schemes influencing net profit margins. Price erosions are ongoing due to biosimilar and generic product entry, particularly in mature markets.

Regulatory and Supply Chain Considerations

Dopamine hydrochloride in Dextrose 5% in Plastic Containers is classified as a cytotoxic, sterile injectable. Manufacturing adheres to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines. Recent regulatory shifts focus on batch consistency, sterility assurance, and container compatibility.

Supply chain disruptions, notably COVID-19-related manufacturing delays and raw material shortages, have caused price volatility and stock shortages historically. Recent efforts include increased inventory buffers and diversified sourcing.

Investment and R&D Trajectory

No significant R&D pipelines target novel formulations of dopamine hydrochloride; the focus remains on production process enhancements, stability improvements, and cost reduction strategies. Investment trends favor capacity expansion in emerging markets.

Financial Metrics and Profitability Estimates

• Gross margins for leading producers hover around 40%, influenced by raw material costs and manufacturing expenses.
• Net profit margins range between 15-20%, subject to regional reimbursement rates and cost controls.
• Capital expenditure (CapEx) investments are focused on sterile manufacturing facilities, with several projects allocated $50-$100 million annually to expand capacity.

Market Risks

Key risks include regulatory changes, patent expirations, and increased competition from biosimilars or alternative therapies such as norepinephrine or vasopressin. Pricing pressures from healthcare payers and global economic fluctuations could compress margins.

---

Key Takeaways

• The global demand for dopamine hydrochloride in Dextrose 5% exceeds $250 million annually, with steady growth expected.
• The market is concentrated among top global manufacturers with high barriers to entry.
• Price sensitivity and reimbursement policies significantly impact revenue and profitability.
• Supply chain stability and regulatory compliance are critical operational considerations.
• R&D efforts are minimal outside process improvements, focusing on capacity and cost efficiencies.

---

FAQs

1. What factors will drive market growth for dopamine hydrochloride in the next five years?
Demand will rise due to increasing critical care cases globally, aging populations, and broader hospital ICU capabilities.

2. What are the primary barriers to market entry?
Stringent regulatory requirements, manufacturing complexity, and established relationships of current market leaders.

3. How is pricing expected to evolve?
Pricing may decline gradually due to biosimilar entry and competitive pressures, especially in mature markets.

4. What are the risks for investors in this market?
Regulatory changes, patent expirations, supply chain disruptions, and increased competition.

5. Are there any significant R&D initiatives in this space?
The focus remains on optimizing manufacturing processes; no major new therapeutic formulations are currently under development.

---

Citations

[1] Market Research Future, "Global Dopamine Hydrochloride Market," 2023.
[2] IQVIA, "Hospital Injectable Market Data," 2022.
[3] Pfizer Annual Reports, 2022.
[4] FDA Drug Approval Database, 2022.
[5] GlobalData Pharma Intelligence, "Critical Care Market Trends," 2023.